RedHill Biopharma Ltd.
RDHL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001553846
In the last 90 days, RedHill Biopharma Ltd. insiders filed 0 open-market purchases and 1 sale; 14 institutions reported holding it in 13F filings for Q2 2026, worth $270.0K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by RedHill Biopharma Ltd. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $1.41K in total
- Insiders trading
- 1
- Net value
- −$1.41K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for RedHill Biopharma Ltd., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Raday Gilead | Chief Operating Officer | 218,780,000 | Jul 13, 2026 | 2 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 13, 2026 (view filing)4:03 PM ET | Jul 10 | 3 days | Raday GileadChief Operating Officer | SSale | −14.1M | $0.0001 | −$1.41K | −6.1%218.8M after | |
| Apr 22, 2026 (view filing) | Apr 6 | 16 daysLate | Raday GileadChief Operating Officer | SSale | −15.7M | $0.00 | $0 | −5.7%261.1M after |